**AI 空间生物标志物分析初创公司 Nucleai 完成 1400 万美元 B+ 轮融资**
AI 空间生物标志物分析领域的创新者 Nucleai 公司于本周三宣布，已成功获得 1400 万美元的 B+ 轮融资。此轮融资由 M Ventures 领投，其他参与投资的现有投资者包括 Section 32、Sanofi Ventures、Debiopharm、复星锐正资本、Vertex Ventures Israel 和 Grove Ventures 等。
Nucleai 是一家专注于利用人工智能和机器学习技术，在细胞和组织层面分析病理图像和空间数据，以预测治疗结果的公司。其独特的方法为精准医疗和个性化治疗提供了新的可能性，这也是当前医疗领域的一个重要趋势。
M Ventures 的投资进一步证明了 Nucleai 在 AI 空间生物标志物分析领域的领导地位。M Ventures 是一家全球性的医疗保健投资公司，其投资领域包括诊断、数字健康和治疗领域。M Ventures 的加入，将为 Nucleai 提供更多的资源和专业知识，以支持其产品的研发和商业化。
Nucleai 的成功融资也反映了其强大的商业模式和市场潜力。自成立以来，Nucleai 已经取得了一系列的成就，包括推出了一系列的产品，并与多家顶级医疗机构和研究机构建立了合作关系。
总的来说，Nucleai 的 B+ 轮融资是一个重要的里程碑，标志着该公司在 AI 空间生物标志物分析领域的进一步发展和扩张。我们期待看到 Nucleai 在未来继续推动医疗领域的创新和发展。
英语如下：
**News Title:** “Nucleai Raises $14 Million in B+ Round to Advance Spatial Biomarker Analysis”
Keywords: Nucleai, B+ round of financing, AI pathology analysis
**News Content:**
**AI Spatial Biomarker Analysis Startup Nucleai Secures $14 Million in B+ Round**
Innovator in AI spatial biomarker analysis, Nucleai, announced on Wednesday that it has successfully raised $14 million in a B+ round of financing. This round of funding was led by M Ventures, with other existing investors including Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, and Grove Ventures participating.
Nucleai is a company focused on using artificial intelligence and machine learning technology to analyze pathological images and spatial data at the cellular and tissue levels to predict treatment outcomes. Its unique approach offers new possibilities for precision medicine and personalized treatment, which is an important trend in the medical field today.
M Ventures’ investment further confirms Nucleai’s leadership in the field of AI spatial biomarker analysis. M Ventures is a global healthcare investment company with investment areas including diagnostics, digital health, and therapeutics. M Ventures’ involvement will provide Nucleai with additional resources and expertise to support the research, development, and commercialization of its products.
Nucleai’s successful financing also reflects its strong business model and market potential. Since its inception, Nucleai has achieved a series of milestones, including the launch of several products and the establishment of collaborations with several top medical institutions and research organizations.
Overall, Nucleai’s B+ round of financing is a significant milestone, marking further development and expansion of the company in the field of AI spatial biomarker analysis. We look forward to seeing Nucleai continue to drive innovation and development in the medical field in the future.
【来源】https://www.calcalistech.com/ctechnews/article/r11brac1a
Views: 2